DenmarkDenmark

Bavarian Nordic Receives US-Patent

06.08.2004

Copenhagen - Bavarian Nordic A/S has been recently issued a patent on its proprietary MVA-BN® technology by the United States Patent and Trademark Office which grants exclusive rights to the Danish company and claims MVA-BN® and derivatives thereof. Safety in humans continues to be the overriding challenge in vaccine development and production.
The patent grant to the MVA-BN virus, which is non-replicative in humans, acknowledges the novelty and utility of such a virus exhibiting the demonstrated safety profile of the MVA-BN technology and other claimed MVA viruses with similar characteristics. The patent includes the use of MVA-BN as a smallpox vaccine Imva-mune™, and extends to its use as a vector technology for developing recombinant vaccines against viral infectious diseases, such as HIV, Dengue Fever, Japanese Encephalitis. The patent covers the use of the MVA-BN technology in generating immunity in healthy and immune compromized subjects and inducing immunity through priming and boosting vaccination schedules. “With the issuance of this broad patent to the MVA-BN virus and its like acting derivatives, it will be difficult for others to develop and produce a safe and effective MVA-based vaccine without a license under this patent,” said CEO Peter Wulff.
The patent was followed by a fast track designation from the FDA for Imvamune, which will not impact the company's financial projections for 2004 of revenues of Euro18.8 million. Bavarian Nordic also entered into a collaboration on Imvamune with Glaxo-Smith-Kline (GSK) in July. GSK will manufacture and market the vaccine to international markets, including North and South America, Japan and a number of important EU-markets, including the UK and France. The Danish company will manufacture and market Imvamune to all German-speaking, Nordic and Baltic countries, China, the Middle East and South East Asia.

DenmarkDenmark

07.03.2012

Bagsvaerd/Bangalore – Danish Novozymes A/S has begun a new collaboration with Indian Sea6 Energy. The companies will jointly develop enzymes to convert seaweed-based carbohydrates to sugar, which can then be fermented to produce...

DenmarkDenmark

06.03.2012

Prague/Turku/Copenhagen – Danish pharmaceutical company H. Lundbeck A/S yesterday unveiled clinical data on its potential blockbuster drug nalmefene at the 2012 European Congress of Psychiatry clinical in Prague. While Lundbeck...

DenmarkDenmark

05.03.2012

Copenhagen – With the in vitro proof of concept for an undisclosed antibody target, Genmab A/S has reached the second milestone in its collaboration with H. Lundbeck A/S. Genmab will now receive a €1m payment. Under the...

DenmarkDenmark

01.02.2012

Copenhagen/Bangalore – Biofuels need reliable sources of biomass. Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory research agreement with Sea6 Energy from India. The...

DenmarkDenmark

02.01.2012

Copenhagen – Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharma’s GLP-2 (glucagone-like peptide 2) peptide antagonist Elsiglutide (ZP1846). The completion of the study, which was...

DenmarkDenmark

23.12.2011

Copenhagen - An alliance of giants will take a thorough look into biofuels for the maritime sector. The leading enzyme producer Novozymes will team up with parts of the Danish shipping industry, including the world’s largest...

DenmarkDenmark

17.12.2011

Copenhagen/Paris – Danish biopharma­ceuticals company Zealand Pharma A/S has received some positive news. Ever since French partner Sanofi Aventis submitted a marketing authorisation application for Lyxumia (lixisenatide) in...

DenmarkDenmark

07.11.2011

Copenhagen/Paris - The cooperation between Danish biopharmaceutical company Zealand Pharma and French drugmaker Sanofi has borne its first fruit. Sanofi has submitted a marketing authorisation application for Lyxumia...

DenmarkDenmark

01.10.2011

Copenhagen/Ingelheim – Danish HTS expert Nuevolution A/S has signed a license agreement with drugmaker Boeh­ringer Ingelheim (BI). The German pharma company will use Nuevolution’s proprietary Chemetics drug discovery technology...

DenmarkDenmark

25.08.2011

Bagsværd - Novo Nordisk is investing around €134m in a new corporate centre in the Copenhagen suburb Bagsværd. The new office premises will concentrate the top management and 1,100 administrative employees which are currently...

Displaying results 1 to 10 out of 194

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-denmark/article/bavarian-nordic-receives-us-patent.html

Events

All Events

Stock list

All quotes

TOP

  • EVOTEC3.94 EUR8.54%
  • VITA 343.90 EUR4.00%
  • SANTHERA86.50 CHF3.59%

FLOP

  • WILEX2.30 EUR-2.54%
  • 4SC1.22 EUR-2.40%
  • ADDEX3.99 CHF-1.97%

TOP

  • SANTHERA86.50 CHF35.2%
  • BB BIOTECH144.50 EUR8.9%
  • ADDEX3.99 CHF4.5%

FLOP

  • WILEX2.30 EUR-23.1%
  • 4SC1.22 EUR-15.9%
  • MOLOGEN7.84 EUR-13.8%

TOP

  • SANTHERA86.50 CHF3612.4%
  • CO.DON2.57 EUR221.2%
  • PAION2.46 EUR182.8%

FLOP

  • CYTOS0.26 CHF-93.4%
  • MEDIGENE4.55 EUR-67.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 28.08.2014


Current issue

All issues

Product of the week

Products